Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2016 7
2017 19
2018 36
2019 29
2020 22
2021 25
2022 17
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

138 results
Results by year
Filters applied: . Clear all
Page 1
Deutetrabenazine Therapy and CYP2D6 Genotype.
Dean L. Dean L. 2019 May 1. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2019 May 1. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 31046213 Free Books & Documents. Review.
Deutetrabenazine (brand name Austedo) is used to treat chorea associated with Huntington disease (HD) and tardive dyskinesia (TD). ...The 2018 FDA-approved drug label for deutetrabenazine states that the daily dose of deutetrabenazine should not exceed 36 mg
Deutetrabenazine (brand name Austedo) is used to treat chorea associated with Huntington disease (HD) and tardive dyskinesia (TD). ..
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
Huntington Study Group; Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Huntington Study Group, et al. JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655. JAMA. 2016. PMID: 27380342 Free article. Clinical Trial.
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. ...Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia. ...
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. ...Adv …
Deutetrabenazine for the treatment of Huntington's chorea.
Bashir H, Jankovic J. Bashir H, et al. Expert Rev Neurother. 2018 Aug;18(8):625-631. doi: 10.1080/14737175.2018.1500178. Epub 2018 Jul 17. Expert Rev Neurother. 2018. PMID: 29996061 Review.
Chorea is the most common motor manifestation of HD and may interfere with daily activities, reduce quality of life, and cause injury. Areas covered: Deutetrabenazine is the first deuterated drug and second drug after tetrabenazine, the classic vesicular monoamine transpor …
Chorea is the most common motor manifestation of HD and may interfere with daily activities, reduce quality of life, and cause injury. Areas …
Deutetrabenazine in the treatment of Huntington's disease.
Richard A, Frank S. Richard A, et al. Neurodegener Dis Manag. 2019 Feb;9(1):31-37. doi: 10.2217/nmt-2018-0040. Epub 2019 Jan 9. Neurodegener Dis Manag. 2019. PMID: 30624137 Review.
Deutetrabenazine (DTBZ) is a US FDA-approved treatment for chorea in Huntington's disease. ...
Deutetrabenazine (DTBZ) is a US FDA-approved treatment for chorea in Huntington's disease. ...
Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
Heo YA, Scott LJ. Heo YA, et al. Drugs. 2017 Nov;77(17):1857-1864. doi: 10.1007/s40265-017-0831-0. Drugs. 2017. PMID: 29080203 Review.

In both trials, with the exception of somnolence, individual neuropsychiatric adverse events typically occurred in < 7% of deutetrabenazine recipients; in FIRST-HD, there was no significant difference in the incidence of individual neuropsychiatric events between the

In both trials, with the exception of somnolence, individual neuropsychiatric adverse events typically occurred in < 7% of deutetraben

deutetrabenazine for the treatment of chorea associated with Huntington's disease.
Gupta H, Perkins W, Stark C, Kikkeri S, Kakazu J, Kaye A, Kaye A. Gupta H, et al. Health Psychol Res. 2022 Jun 28;10(3):36040. doi: 10.52965/001c.36040. eCollection 2022. Health Psychol Res. 2022. PMID: 35774908 Free PMC article.
This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington's disease. ...Chorea is one of the many manifestations that significantly alter the quality of life of many patients. Deutetrabenazine
This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington' …
Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
Paton DM. Paton DM. Drugs Today (Barc). 2017 Feb;53(2):89-102. doi: 10.1358/dot.2017.53.2.2589164. Drugs Today (Barc). 2017. PMID: 28387387 Review.
Deutetrabenazine is a derivative of tetrabenazine in which two trideuteromethoxy groups substitute two methoxy groups. ...Unlike tetrabenazine, deutetrabenazine has no effect on the QT interval. Treatment with deutetrabenazine significantly improved chorea in
Deutetrabenazine is a derivative of tetrabenazine in which two trideuteromethoxy groups substitute two methoxy groups. ...Unlike tetr
Valbenazine and Deutetrabenazine for Tardive Dyskinesia.
Touma KTB, Scarff JR. Touma KTB, et al. Innov Clin Neurosci. 2018 Jun 1;15(5-6):13-16. Innov Clin Neurosci. 2018. PMID: 30013814 Free PMC article. Review.
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treat …
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or disconti …
Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
Claassen DO, Philbin M, Carroll B. Claassen DO, et al. Expert Opin Pharmacother. 2019 Dec;20(18):2209-2221. doi: 10.1080/14656566.2019.1674281. Epub 2019 Oct 15. Expert Opin Pharmacother. 2019. PMID: 31613641 Review.
The safety profile of deutetrabenazine in clinical trials is similar to that of placebo. Long-term extension studies in both HD-associated chorea and TD show consistent efficacy and safety. Deutetrabenazine will likely be an integral part of the treatment strategy f …
The safety profile of deutetrabenazine in clinical trials is similar to that of placebo. Long-term extension studies in both HD-assoc …
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE. Fernandez HH, et al. J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1317-1323. doi: 10.1136/jnnp-2018-319918. Epub 2019 Jul 10. J Neurol Neurosurg Psychiatry. 2019. PMID: 31296586 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD). METHOD: Patients with TD who completed the 12 week, phase 3, placebo-controlled trials were eligible to enter this open-label, single-arm study. ...The me …
OBJECTIVE: To evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD). METHOD: Patien …
138 results